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Background: To assess the feasibility and potential impact on target delineation of respiratory-gated (4D) contrast-
enhanced 18Fluorine fluorodeoxyglucose (FDG) positron emission tomography - computed tomography (PET-CT), in
the treatment planning position, for a prospective cohort of patients with lower third oesophageal cancer.
Methods: Fifteen patients were recruited into the study. Imaging included 4D PET-CT, 3D PET-CT, endoscopic
ultrasound and planning 4D CT. Target volume delineation was performed on 4D CT, 4D CT with co-registered 3D
PET and 4D PET-CT. Planning target volumes (PTV) generated with 4D CT (PTV4DCT), 4D CT co-registered with 3D
PET-CT (PTV3DPET4DCT) and 4D PET-CT (PTV4DPETCT) were compared with multiple positional metrics.
Results: Mean PTV4DCT, PTV3DPET4DCT and PTV4DPETCT were 582.4 ± 275.1 cm
3, 472.5 ± 193.1 cm3 and 480.6 ± 236.9 cm3
respectively (no significant difference). Median DICE similarity coefficients comparing PTV4DCT with PTV3DPET4DCT,
PTV4DCT with PTV4DPETCT and PTV3DPET4DCT with PTV4DPETCT were 0.85 (range 0.65–0.9), 0.85 (range 0.69–0.9) and 0.88
(range 0.79–0.9) respectively. The median sensitivity index for overlap comparing PTV4DCT with PTV3DPET4DCT, PTV4DCT
with PTV4DPETCT and PTV3DPET4DCT with PTV4DPETCT were 0.78 (range 0.65–0.9), 0.79 (range 0.65–0.9) and 0.89
(range 0.68–0.94) respectively.
Conclusions: Planning 4D PET-CT is feasible with careful patient selection. PTV generated using 4D CT, 3D PET-CT and
4D PET-CT were of similar volume, however, overlap analysis demonstrated that approximately 20% of PTV3DPETCT and
PTV4DPETCT are not included in PTV4DCT, leading to under-coverage of target volume and a potential geometric miss.
Additionally, differences between PTV3DPET4DCT and PTV4DPETCT suggest a potential benefit for 4D PET-CT.
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Oesophageal cancer is the 8th commonest malignancy
worldwide with approximately 456,000 cases diagnosed in
2012 [1]. Patients with locally advanced distal oesophageal
cancer are increasingly treated with chemo-radiotherapy
either in the neoadjuvant setting prior to definitive surgery
or as stand-alone therapy [1]. Accurate target delineation,
motion assessment and target localisation is a pre-
requisite for high-precision radiotherapy treatment plan-
ning (RTP). Currently intravenous contrast-enhanced
computed tomography (CT) in combination with endo-
scopic ultrasound are the standard techniques used for
definition of gross tumour volume (GTV) prior to radio-
therapy in oesophageal cancer [2]. A margin for micro-
scopic extension is applied, the clinical target volume
(CTV), and finally a margin for mechanical delivery un-
certainties and internal organ motion relating to respira-
tory motion, results in a planning target volume (PTV).
Contouring the GTV on conventional three-dimensional
CT (3D CT) obtained during free-breathing may result in
inaccurate representation of both tumour dimensions and
mean tumour position relative to other organs. Four-
dimensional CT (4D CT) performed with respiratory-
gating, allows CT data acquired during the breathing cycle
to be sub-divided into time-resolved 3D datasets (bins).
The lower oesophagus moves significantly with breathing
and 4D CT facilitates quantification of motion and allows
patient-specific target volume delineation [3–5]. Use of
4D CT in RTP of oesophageal cancer is intended to en-
sure adequate coverage of the moving target volume
within the radiation field and optimises normal tissue
sparing compared to 3D CT [6]. 4D CT is now standard
of care for RTP of lower third oesophageal cancer
patients.
18Fluorine fluorodeoxyglucose (FDG) positron emis-
sion tomography – computed tomography (PET-CT) is
firmly established in guiding optimal management of
radically treatable oesophageal carcinoma [7, 8]. The role
of FDG PET-CT in RTP of oesophageal carcinoma is less
well developed. Preliminary studies evaluating the role
of 3D PET-CT in RTP of oesophageal cancer have re-
ported changes in target volume with potential impact
on treatment planning [9–11]. Two recent studies by
the same group evaluating 4D CT and 3D PET-CT in
RTP of oesophageal cancer have reported that this
combination of techniques impacted on target defin-
ition [12, 13]. However, motion artefacts with 3D PET-
CT can reduce target contrast, overestimate lesion size
and cause inaccurate assessment of standardized uptake
value (SUV) [14]. Hypothetically motion management
with respiratory gating to obtain a 4D PET-CT should
provide additional information for RTP resulting in
more consistent target definition [15]. There is a pau-
city of data in this clinical scenario with a singleretrospective study having assessed dosimetric implica-
tions and another small prospective study evaluating
the potential of 4D PET-CT for target volume delinea-
tion in oesophageal cancer, both showing promise for
target volume definition [16, 17]. The impact of 4D
PET-CT on PTV definition has not yet been reported
in a prospective series to the best of our knowledge.
The purpose of this study was to assess the feasibility
and potential impact on target delineation of contrast-
enhanced 4D PET-CT acquired in the treatment plan-
ning position, for a prospective cohort of patients with
lower third oesophageal cancer.
Methods
Study outline
This was a non-randomised prospective single centre
study in patients with distal oesophageal carcinoma suit-
able for treatment with radiotherapy or concurrent
chemo-radiotherapy (ClinicalTrials.gov identifier –
NCT02285660, Registered 21/10/2014). Trial partici-
pants underwent standard-of-care imaging including 3D
FDG PET-CT, endoscopic ultrasound and radiotherapy
planning 4D CT. A trial-specific contrast-enhanced 4D
FDG PET-CT in the treatment position with limited
coverage of the lower thorax and upper abdomen was
also performed. Subsequent treatment was not affected
by the trial-specific PET-CT and was delivered according
to institutional clinical protocols.
Patient selection and recruitment
Inclusion criteria were as follows: Age ≥ 18 years; World
Health Organization (WHO) performance status 0–2;
histologically proven distal oesophageal carcinoma; clin-
ical decision made to proceed with radiotherapy +/−
concurrent chemotherapy; measurable primary tumour
+/− loco-regional metastatic lymph nodes on standard-
of-care imaging; able to provide fully informed written
consent; able to lie flat for 1 h; not pregnant or breast
feeding. Female patients of childbearing potential agreed
to use effective contraception, were surgically sterile, or
were post-menopausal.
Exclusion criteria included: poorly controlled diabetes;
renal impairment with estimated glomerular filtration
rate < 30 mL/min; allergy to iodinated contrast media.
The study was approved by the regional Research Ethics
Committee (Approval Reference 11/YH/0213). All pa-
tients provided informed written consent prior to trial
entry. A total of 15 patients were recruited between Octo-
ber 2011 and July 2014. All patients provided informed
written consent prior to study entry.
PET-CT technique
4D PET-CT scans were performed using a 64-slice GE Dis-
covery 690 PET-CT scanner (GE Healthcare, Amersham,
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respiratory-gating hardware (Varian Medical Systems Inc.,
Palo Alto, CA, USA), a flat couch top and laser alignment.
Patients were scanned supine in the treatment position;
immobilised with a wing board and both arms raised
above their heads. Serum blood glucose was checked rou-
tinely and imaging was not performed in patients with a
blood glucose level of >10 mmol/L. Patients fasted for at
least 6 h prior to intravenous injection of 400 MBq of
18Fluorine-FDG. Patients were positioned on the hard-top
couch with laser alignment to skin tattoos marked during
standard-of-care radiotherapy planning CT 45 min’ post
injection. A non-contrast CT of the treatment area (lower
thorax/upper abdomen) was obtained using standard set-
tings: 120 kV, variable mA (min 50 max 500, noise index
22.6), tube rotation time 0.4 s, pitch 1.984 with a 2.5 mm
slice reconstruction. Static PET acquisition from mid
thorax to upper abdomen was then performed scanning
in a cranial direction with 23 slices (50% overlap) acquired
over 1 min. 60-min after tracer injection a 4D respiratory-
gated PET acquisition commenced scanning in a cranial
direction over the same volume (20-min acquisition).
Breaths per minute (BPM) were monitored during this
acquisition and average breathing period in seconds (60/
average BPM) was calculated. The cine acquisition param-
eters for 4D CT were based on average breathing period
determined from the 4D PET acquisition. The 4D CT
component was obtained 35 s following a bolus of 100 ml
of iodinated contrast (Niopam 300, Bracco Ltd., High
Wycombe, UK) injected at 2 ml/s using the following set-
tings; 120 kV, 150 mA, tube rotation 0.4 s per rotation,
pitch 1.984, 40 mm detector coverage (centred over the
tumour) with a 2.5 mm helical thickness (16 images per
rotation). Cine duration varied for individual patients
(product of average breathing time and scanner rotation
time, 0.4 s). PET images were reconstructed using a sta-
ndard ordered subset expectation maximization (OSEM)
algorithm with CT for attenuation correction. Both non-
attenuation corrected and attenuation corrected datasets
were reconstructed.
The 4D CT and 4D PET data was divided into 10
phase bins. Post-processing was used to generate an
averaged 3D PET from the 4D PET scan. No co-
registration was necessary as the PET and CT compo-
nents were inherently registered.
Contouring
Contouring was performed using specialized software
(RTx, Mirada Medical, Oxford UK). PET and CT images
were displayed using preset window levels and/or colour
scale per a standardized institutional protocol (Fig. 1).
Patients were contoured per the National Cancer Re-
search Institute (NCRI) UK NeoSCOPE trial protocol
[18]. The tumour length and outlines were derived fromthe diagnostic imaging which included an Endoscopic
Ultrasound, contrast-enhanced CT and 3D PET-CT. The
longest tumour dimension was used for outlining. The
maximal length of the tumour with specific reference to
an anatomical structure e.g. carina or superior aortic
arch was defined on all imaging techniques. This en-
abled the oncologist and radiologist to identify the su-
perior and inferior extent of the diseased oesophagus in
relation to these structures; thereby allowing them to
outline this segment of the entire circumference of
oesophagus to be outlined. All the 4D CT and PET scans
included at least one of the reference structures (e.g.
superior aortic arch or carina) and therefore the target
volumes were produced consistently on each of these
datasets with reference to these structures [2]. Local
nodal involvement was included in the target volume
but more distant nodes were not. An experienced radi-
ation oncologist contoured all target volumes with ac-
cess to clinical details and standard-of-care imaging;
PET-derived contours were generated by the same radi-
ation oncologist contouring with an experienced dual-
certified Nuclear Medicine Physician/Radiologist. GTVs
were delineated on i) 10-phase planning 4D CT, ii) 10-
phase 4D CT inherently co-registered to 3D PET-CT ac-
quired at the same scan session and iii) 4D PET-CT.
CTV was delineated and trimmed to anatomical bound-
aries (vertebrae, pericardium, pleura). 4D datasets from
each series were used to generate an internal target vol-
ume (ITV) encompassing effects of physiological motion
on the CTV. Expansion to PTV was the ITV of each
series with a 5-mm margin in all directions. (Fig. 2). A
minimum interval of 2 weeks was specified between de-
lineation using each different methodology for each pa-
tient, to minimize any potential for intra-observer recall.Positional analysis
Five positional metrics were used to compare target vol-
umes, calculated using ImSimQA software (v3.1.5, On-
cology Systems Limited, Shrewsbury, UK): Dice index
(DICE); sensitivity index (Se.Idx), inclusiveness index
(Inc.Idx), centre of gravity distance (CGD) and mean
distance to conformity (MDC). The Dice index produces
output values ranging from 0 and 1 where 0 represents
two contours with no overlap and 1 represents two con-
tours that are perfectly overlapping [19]. The Se.Idx cal-
culates the overlapping volume between a contour and a
reference contour as a percentage of the volume of the
reference volume. The Inc.Idx is the probability that a
voxel of a contour is really a voxel of a reference con-
tour. CGD is the distance between the geometric centres
of two contours [20]. MDC is the mean of the distances
between contours averaged over all positions not within
the overlapping contour [20].
Fig. 1 Screenshot illustrating specialised software (RTx, Mirada Medical) used to contour 4D PET and CT datasets
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Descriptive statistics (median, range) and Mann-Whitney
test were used to assess for statistically significant di-
fferences between tumour volumes and lengths. Non-
parametric analysis of variance (ANOVA) was used to
assess the statistical significance of positional metrics be-
tween different imaging techniques (Friedman test). Stas-
tistical analysis was performed using IBM SPSS Statistics
(Version 22, IBM Corp, Amonk, NY, USA). A p-value
<0.05 was taken as evidence of statistical significance.Fig. 2 A comparison of PTV contours derived using i) 4D CT data, ii) 4D CTResults
Patient characteristics
Fifteen patients were recruited to the study but only 9
underwent 4D PET-CT imaging for various reasons. Of
the 6 patients who did not undergo 4D PET-CT, 3 with-
drew before scanning; 2 had erratic breathing which made
respiratory gating impossible and 1 patient had very low-
grade tumour uptake having completed induction chemo-
therapy 6 weeks earlier. It was decided to discontinue data
acquisition following the initial static PET for this patient.co-registered to 3D PET-CT and iii) 4D CT and 4D PET
Table 2 Volumetric and length comparison of GTV, ITV and PTV
structures; there were no statistically significant differences
(Mann-Whitney Test) between the volumes/lengths when
comparing structures from the 3D PET-CT to the 4D CT and
structures from the 4D PET-CT to the 4D CT
Volume (cm3) Length (cm)
GTV ITV PTV GTV ITV PTV
4D CT 108.1 271.8 528.4 5.4 10.0 10.9
3D PET-CT 82.6 239.8 472.5 6.4 10.1 11.1
p-value 0.89 0.95 0.95 0.52 0.8 0.7
4D PET-CT 88.3 236.0 480.6 5.1 9.6 10.6
p-value 0.85 0.57 0.75 0.95 0.7 0.85
GTV gross tumour volume, ITV internal target volume, PTV planning
target volume
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ratic breathing leading to technical difficulties with acqui-
sition of the 4D CT component. Consequently, only 7
patients had complete datasets suitable for comparative
analysis. 6 of these patients were treated with curative in-
tent and 1 patient underwent palliative treatment. Patient
characteristics are detailed in Table 1.
Volumetric comparison
Table 2 demonstrates the average delineated tumour vol-
umes (GTV, ITV, PTV) and tumour length on the 3 dif-
ferent scans. PTV defined using 3D and 4D PET-CT
were smaller; 3D PET-CT (PTV median 396.9, range
273.5–704.3 cm3): 4D PET-CT (482.1, 233.8–825.8 cm3)
in comparison to PTV delineated on 4D CT (508.9,
267.5–907.1 cm3). Despite this there was no statistically
significant difference between PTV volumes across the 3
methods (Mann-Whitney test). Tumour length compari-
son between the different modalities was also not statis-
tically significantly different.
Positional analysis
Median DICE similarity coefficients comparing PTV4DCT
with PTV3DPET4DCT, PTV4DCT with PTV4DPETCT and
PTV3DPET4DCT with PTV4DPETCT were 0.85 (range 0.65–
0.9), 0.85 (0.69–0.9) and 0.88 (0.79–0.9) respectively. The
median sensitivity index for overlap comparing
PTV3DPET4DCT and PTV4DPETCT with PTV4DCT was 0.78
(0.7–0.91) and 0.79 (0.65–0.92) respectively. The median
sensitivity index for overlap comparing PTV3DPET4DCT
with PTV4DPETCT was 0.89 (0.68–0.98). The median
centre of gravity distance was 5.19 mm (1.6–27.3 mm) for
the PTV4DCT to PTV4DPETCT structures, 3.52 mm (2.9–
7.8 mm) for PTV3DPET4DCT to PTV4DPETCT structures and
4.97 mm (1.6–28.2 mm) for the PTV4DCT toTable 1 Baseline characteristics of the 7 patients studied
Characteristic Number
Mean age in years (range) 71 (68–74)
Histology
Adenocarcinoma 6 (85.7%)
Squamous carcinoma 1 (14.3%)
Stage (TNM)
T2 N0 M0 2 (28.6%)
T3 N0 M0 2 (28.6%)
T3 N1 M0 2 (28.6%)
T3 N3 M1 1 (14.3%)
Nodal disease at baseline
Yes 3 (42.9%)
No 4 (57.1%)
Mean primary tumour SUVmax (Range) 12.8 (5.5–26.2)PTV3DPET4DCT structures. The median mean distance to
conformity was 9.15 mm (5–22.9 mm) for the
PTV3DPET4DCT to PTV4DCT structures, 10.68 mm (5.2–
22.6 mm) for the PTV4DPETCT to PTV4DCT and 7.41 mm
(5.2–10.8 mm) for the PTV3DPET4DCT to PTV4DPETCT.
Table 3 illustrates positional metric differences be-
tween 4D CT and 4D PET-CT PTV structures and
Table 4 demonstrates the relative positional metric dif-
ferences between 3D PET-CT and 4D PET-CT PTV
structures. Table 5 compares the positional metrics be-
tween 4D CT and 3D PET-CT PTV structures. There
was no statistically significant difference (Friedman test)
between the 5 target volume positional metrics defined
on each of the different CT and PET combinations
(Table 6).
Discussion
Respiratory motion affects imaging quality which is of
direct relevance in RTP of potentially mobile tumours
[21]. 4D CT guides generation of patient specific vol-
umes accounting for physiological organ motion and is
recommended in target definition protocols for lower
oesophageal carcinoma [22]. Incorporating PET into the
planning process has potential to improve the accuracyTable 3 Comparison of PTV4DCT and PTV4DPETCT structures
Patient DICE Se.Idx Inc.Idx CGD (mm) MDC (mm)
1 0.9 0.91 0.89 1.73 5.23
2 0.8 0.74 0.87 9.25 12.8
3 0.89 0.85 0.94 5.19 11.45
4 0.85 0.79 0.93 1.64 10.03
5 0.69 0.65 0.74 27.29 22.56
6 0.89 0.92 0.87 2.9 5.94
7 0.82 0.77 0.88 9.33 10.68
Median 0.85 0.79 0.88 5.19 10.68
DICE Dice index, Se.Idx sensitivity index, Inc.Idx inclusiveness index, CGD centre
of gravity distance, MDC mean distance to conformity, SD standard deviation
Table 4 Comparison of PTV3DPET4DCT and PTV4DPETCT structures
Patient DICE Se.Idx Inc.Idx CGD (mm) MDC (mm)
1 0.9 0.89 0.92 2.91 5.19
2 0.9 0.92 0.88 3.25 8.35
3 0.9 0.98 0.83 6.44 6.46
4 0.88 0.83 0.93 5.49 7.41
5 0.79 0.68 0.95 3.1 7.57
6 0.82 0.94 0.73 3.52 7.4
7 0.81 0.75 0.87 7.78 10.76
Median 0.88 0.89 0.88 3.52 7.41
DICE Dice index, Se.Idx sensitivity index, Inc.Idx inclusiveness index, CGD centre
of gravity distance, MDCmean distance to conformity, SD standard deviation
Table 6 Positional metric analysis; there were no statistically
significant differences (Friedman Test) between the 5 metrics
comparing PTV structures between 3D PET-CT to 4D CT, 4D







DICE Dice index, Se.Idx sensitivity index, Inc.Idx inclusiveness index, CGD centre
of gravity distance, MDC mean distance to conformity, PTV planning
target volume
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superior to combining 3D PET with 4D–CT [12, 13,
15–17]. The aims of this pilot study were to assess the
feasibility and impact of incorporating 4D PET-CT into
the radiotherapy planning pathway of patients with
lower oesophageal carcinoma.
This study has confirmed that incorporating 4D PET-
CT into the RTP pathway of patients with lower
oesophageal carcinoma is feasible. However, careful
patient selection is important as it may not be possible in
patients with an irregular breathing pattern. This pre-
vented or significantly degraded 4D imaging in 4 patients
in our study. Low-grade tumour uptake was also a limita-
tion. The only other prospective study of 4D PET-CT in
this setting reported 6/18 patients (33.3%) had imaging
unsuitable for contouring for similar reasons [17]. Their
study focused on optimal thresholding of PET data for
GTV delineation and reported that a threshold setting of
20% standardised uptake value (SUV) or a fixed threshold
of SUV 2.5 best correlated with tumour length, volume ra-
tio and conformality index [17].
In this study 4D CT and PET data acquisitions were
acquired at the same attendance with the patient in the
radiotherapy treatment position with immobilization to
ensure inherent co-registration. Post-processing was
used to generate an averaged 3D PET from the 4D PETTable 5 Comparison of PTV4DCT and PTV3DPET4DCT structures
Patient DICE Se.Idx Inc.Idx CGD (mm) MDC (mm)
1 0.87 0.9 0.85 4.02 5.89
2 0.77 0.7 0.86 11.23 15.44
3 0.85 0.76 0.98 4.97 10.11
4 0.9 0.88 0.92 7.03 9.15
5 0.65 0.72 0.59 28.17 22.94
6 0.85 0.78 0.94 4.19 6.8
7 0.9 0.91 0.89 1.61 5.04
Median 0.85 0.78 0.89 4.97 9.15
DICE Dice index, Se.Idx sensitivity index, Inc.Idx inclusiveness index, CGD centre
of gravity distance, MDC mean distance to conformity, SD standard deviationscan. This methodology should largely obviate any po-
tential error introduced by registration of separately ac-
quired CT and PET data. To the best of our knowledge,
this is the first study to report positional metric com-
parison of tumour volumes delineated on 4D CT and 4D
PET-CT in lower oesophageal carcinoma. Concordance
between the contoured volumes on different studies
were high with no statistical significance reached be-
tween PTV measured on each combination for the 5
positional metrics analysed, although the small sample
size limits the value of statistical analysis; overlap indices
were greatest between 3D PET-CT and 4D PET-CT
(median DICE similarity coefficient 0.88, median sensi-
tivity index 0.89) and slightly lower when comparing 4D
CT with 3D PET-CT (median DICE similarity coefficient
0.85, median sensitivity index 0.78) and 4D CT with 4D
PET-CT (median DICE similarity coefficient 0.85, me-
dian sensitivity index 0.79). Median centre of gravity dis-
tance was smallest for PTV3DPET4DCT to PTV4DPETCT
structures (3.52 mm) and greatest for PTV4DCT to
PT4DPET4DCT structures (5.19 mm). The median mean
distance to conformity was lowest (7.41 mm) for the
PTV3DPET4DCT to PTV4DPETCT and highest for the
PTV4DPETCT to PTV4DCT (10.68 mm). The observed dif-
ferences between PTVs are potentially clinically import-
ant; for example, the median sensitivity index of 0.79
between 4D CT and 4D PET-CT implies 21% of the
PTV4DPETCT is not included within the PTV4DCT. The
use of 4D PET-CT might minimise the risk of geometric
miss but this has not been confirmed and requires fur-
ther evaluation.
A key unanswered question is whether 4D PET-CT
provides incremental benefit compared with 4D CT and
3D PET-CT. Although positional metrics comparing PTVs
generated using these methods suggested differences were
small, the sensitivity index of 0.89 (implying that 11% of the
PTV4DPETCT was not included within PTV3DPET4DCT) sug-
gests that there might be a potential additional role for the
use of 4D PET-CT but the cohort is too small to draw con-
clusions on this. A small retrospective study of 4 patients
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delineated on inhale and exhale phase 4D PET-CT deform-
ably co-registered with a planning CT were up to 30%
smaller in 3 of 4 patients on the exhale plan with potential
for dose sparing to organs at risk [16]. Conversely, a pilot
study of 4D PET-CT for delineation of ITV in lung tu-
mours reported concordance between different contoured
volumes assessed using Dice coefficient and 3D PET-CT
was consistently found to underestimate ITV compared to
4D PET-CT [23].
An important issue regarding use of PET in tumour
volume delineation is the methodology employed to de-
fine the functional volume of interest. Several different
methods have been proposed varying by tumour site and
range from simplistic manual delineation to fully auto-
mated adaptive thresholding techniques [24, 25]. To date
there is no clear consensus on which method is best and
some nervousness about automatic delineation techniques
[26]. Expert manual delineation by an experienced clinical
oncologist in collaboration with a Radiologist/Nuclear
Medicine Physician is established best practice [27]. In the
absence of a widely accepted method in this clinical sce-
nario, we made a pragmatic decision to manually contour
PET volumes collaboratively as a Radiotherapist/Radiologist
pair. Images were displayed using preset window levels
and/or colour scale as per a standardized protocol which
has been used in routine clinical practice for many years at
our institution. Comparison of different methods for
tumour volume segmentation has been previously reported
in this setting albeit without pathological validation [17]. As
a consequence this aspect was not a focus in this study.
PTVs delineated using 4D CT are often smaller than
with 3D CT and doses to organs at risk in oesophageal
cancer (lungs, liver and heart) are reduced using 4D CT
which may facilitate dose escalation without significant
collateral damage [28]. In this study, average tumour
length was smallest on 4D PET-CT (range 5.1–10.6 cm),
slightly larger (difference not statistically significant) on
4D CT (range 5.4–10.9 cm) and larger still on 3D PET-
CT (range 6.4–11.1 cm). Tumour volumes were also
consistently smaller on 4D PET-CT (average PTV
480.6 cm3) compared to 4D CT (average PTV
528.4 cm3), although the difference between volumes
was not statistically significant. 3D CT represents a ran-
dom snapshot during the breathing cycle whereas 4D
CT is a selected series of snapshots at points on the
breathing cycle. PET is different; 3D PET is a time-
averaged image (showing motion blur covering the full
breathing cycle) and 4D PET is a time-averaged image
covering a phase bin where the amount of motion blur
depends on degree of motion within that bin. Differ-
ences between volumes in part reflects this but also that
PET and CT are demonstrating different tumour charac-
teristics which are unlikely to inherently have the samevolume but should provide complimentary information.
4D PET-CT volumes may have been smallest due to the
benefit of PET and CT information but with a reduction
in the motion blurring of 3D PET.
The study has limitations particularly the small cohort
size and absence of histological validation of tumour vol-
umes which is frequently the case in feasibility studies.
Despite these limitations this small study has proven the
feasibility of the technique and confirmed that tumour
volume delineation using 4D PET-CT results in PTV
differences compared with either 4D CT alone or 4D CT
combined with 3D PET. Our data add to a recent litera-
ture review of the potential utility of 4D PET-CT in
GTV delineation of intra-thoracic tumours which con-
cluded that this may be the best approach currently
available but warrant further investigation in future pro-
spective studies [29]. Further work to establish if dose
distribution varies for different PTVs and to evaluate
outcome in a larger patient cohort with or without 4D
PET-CT as part of RTP should be considered.
Conclusions
Acquisition of a planning 4D PET-CT is feasible with care-
ful patient selection. PTVs generated using 4D CT, 4D CT
co-registered with 3D PET-CT, and 4D PET-CT were of
similar volume; however, percentage overlap analysis dem-
onstrates that approximately 20% of the PTV3DPET4DCT and
PTV4DPETCT are not included in the PTV4DCT, theoretically
leading to under-coverage of the target volume and a po-
tential geometric miss. The current study is too small to
draw any conclusions about clinical benefit and further
investigation is warranted.
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